Top Authors

• Most frequent coverage on MKGAY.PK

• 
  Mike Havrilla (1961 followers)

  • Mentor Capital Cancer Vaccine Investing Update (Wed, Dec 23)
  • BioMed Updates: Merck KGaA, BioMarin, Cytori and Theravance (Mon, Nov 30)
  • FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex (Tue, Jun 23)

  More by Mike Havrilla on MKGAY.PK »
• 
  Richard Sater (19 followers)

  • Novartis: Powering into the Multiple Sclerosis Market (Tue, Sep 8)
  • BioMS: Hype or Hope? (Mon, Jul 13)
  • New MS Therapies: A Hard Pill to Swallow? (Sun, Apr 19)

  More by Richard Sater on MKGAY.PK »
• 
  Eben Tessari (28 followers)

  • EMD Serono Snags US license for Tesamorelin From Theratechnologies (Fri, Oct 31)

  More by Eben Tessari on MKGAY.PK »

• Most followed authors on MKGAY.PK

• 
  Mike Havrilla (1961 followers)

  • Mentor Capital Cancer Vaccine Investing Update (Wed, Dec 23)
  • BioMed Updates: Merck KGaA, BioMarin, Cytori and Theravance (Mon, Nov 30)
  • FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex (Tue, Jun 23)

  More by Mike Havrilla on MKGAY.PK »
• 
  VFC's Stock House (1163 followers)

  • Long Term Results of Oncothyreon's Stimuvax Look Promising (Sun, May 31)

  More by VFC's Stock House on MKGAY.PK »
• 
  EP Vantage (71 followers)

  • Merck KGaA: Another Stumble Leaves Investors Worried (Tue, Dec 1)

  More by EP Vantage on MKGAY.PK »

• Newest authors on MKGAY.PK

• 
  VFC's Stock House (1163 followers)

  • Long Term Results of Oncothyreon's Stimuvax Look Promising (Sun, May 31)

  More by VFC's Stock House on MKGAY.PK »
• 
  Richard Sater (19 followers)

  • Novartis: Powering into the Multiple Sclerosis Market (Tue, Sep 8)
  • BioMS: Hype or Hope? (Mon, Jul 13)
  • New MS Therapies: A Hard Pill to Swallow? (Sun, Apr 19)

  More by Richard Sater on MKGAY.PK »
• 
  EP Vantage (71 followers)

  • Merck KGaA: Another Stumble Leaves Investors Worried (Tue, Dec 1)

  More by EP Vantage on MKGAY.PK »

• Most commented on MKGAY.PK

• 
  Richard Sater (19 followers)

  • Novartis: Powering into the Multiple Sclerosis Market (Tue, Sep 8)
  • BioMS: Hype or Hope? (Mon, Jul 13)
  • New MS Therapies: A Hard Pill to Swallow? (Sun, Apr 19)

  More by Richard Sater on MKGAY.PK »
• 
  Mike Havrilla (1961 followers)

  • Mentor Capital Cancer Vaccine Investing Update (Wed, Dec 23)
  • BioMed Updates: Merck KGaA, BioMarin, Cytori and Theravance (Mon, Nov 30)
  • FDA Calendar Updates: Amgen, Amicus, Oncothyreon and Medarex (Tue, Jun 23)

  More by Mike Havrilla on MKGAY.PK »
• 
  VFC's Stock House (1163 followers)

  • Long Term Results of Oncothyreon's Stimuvax Look Promising (Sun, May 31)

  More by VFC's Stock House on MKGAY.PK »